Geneoscopy Advances Mission to Transform Gastrointestinal Health at Digestive Disease Week 2024
24 Mayo 2024 - 8:05AM
Business Wire
Company highlights capabilities of noninvasive
stool-based RNA technology platform for improving patient outcomes
in IBD and CRC
Geneoscopy, Inc., a life sciences company focused on developing
diagnostic tests for the advancement of gastrointestinal health,
presented key research findings that showcased the capabilities of
its stool-based RNA platform at the Digestive Disease Week (DDW)
2024 meeting. Results showed that Geneoscopy’s novel RNA technology
can assess therapeutic response for patients with inflammatory
bowel disease (IBD) and transform colorectal cancer (CRC)
screening, potentially impacting millions of patients in need.
Geneoscopy also participated in three invite-only panel
presentations hosted by Colorectal Cancer Alliance, Fight CRC, and
Johnson & Johnson.
“Participating and presenting at DDW offered an incredible
opportunity to highlight the potential of Geneoscopy’s noninvasive
RNA technology in transforming gastrointestinal health,” said Dr.
Erica Barnell, Chief Science and Medical Officer at Geneoscopy.
“Our company is at the leading edge of a new frontier where
healthcare providers are empowered with actionable insights from
innovative tests that help prevent, detect, and monitor disease,
ultimately improving patient outcomes.”
A poster, titled Stool-derived eukaryotic RNA assay approximates
disease activity index and predicts therapeutic response in
patients with Crohn’s disease on advanced therapies, found that the
RNA signatures showed high accuracy in distinguishing subjects with
active disease from those in remission with further
subcategorization of active inflammation based on disease severity.
This method demonstrated consistent detection of RNA biomarkers in
stool samples and effective prediction of therapeutic response
across different targeted therapies.
A second poster presentation, titled Development of a
second-generation multi-target stool RNA test (ColoSense 2.0) for
colorectal cancer screening, demonstrated a preliminary ability to
leverage bio-banked stool samples to improve the accuracy of
Geneoscopy’s RNA-based ColoSense test, which recently received FDA
approval for CRC screening of average-risk individuals over the age
of 45. Novel stool-based RNA biomarkers improved sensitivity for
detecting CRC and advanced adenomas while maintaining high
specificity for no lesions on colonoscopy. Ongoing efforts aim to
enhance the ColoSense performance by identifying novel biomarkers
to further refine its diagnostic accuracy utilizing next-generation
sequencing technology.
“In addition to presenting these impactful study results at the
DDW meeting in Washington D.C., our team engaged with advocacy
partners, policymakers, professional societies, and legislative
bodies to address the pressing issues in gastrointestinal health,”
said Matt Sargent, Chief Commercial Officer at Geneoscopy. “As the
number of Americans suffering from gastrointestinal diseases
increases, it’s crucial that we come together and take the needed
steps to educate and offer both physicians and their patients
better, more convenient, and personalized treatment options.”
Studies have shown that approximately 30% of IBD patients do
not respond to initial treatment, highlighting a critical need for
tools to inform therapy selection. Additionally, compliance rates
for preventative measures like CRC screening remain low. More than
44 million Americans at average risk for CRC remain unscreened
despite screening's vital role in early detection and prevention.
Geneoscopy’s technology provides reliable, scalable, and
cost-effective evaluation of RNA biomarkers from stool samples,
delivering the ideal platform for developing diagnostic tests for
gastrointestinal health.
About DDW
Digestive Disease Week® (DDW) is the largest international
gathering of physicians, researchers and academics in the fields of
gastroenterology, hepatology, endoscopy and gastrointestinal
surgery. Jointly sponsored by the American Association for the
Study of Liver Diseases (AASLD), the American Gastroenterological
Association (AGA), the American Society for Gastrointestinal
Endoscopy (ASGE) and the Society for Surgery of the Alimentary
Tract (SSAT), DDW is an annual in-person and online meeting. This
year’s meeting was held from May 18-21, 2024 in Washington, D.C.
and showcased more than 4,400 abstracts and hundreds of lectures on
the latest advances in GI research, medicine and technology. More
information can be found at www.ddw.org.
About Geneoscopy, Inc.
Geneoscopy Inc. is a life sciences company focused on developing
diagnostic tests for gastrointestinal health. Leveraging its
proprietary, patented stool-derived eukaryotic RNA (seRNA)
biomarker platform, Geneoscopy’s mission is to empower patients and
providers to transform gastrointestinal health through innovative
diagnostics. The company’s FDA-approved ColoSense™ test uses a
proprietary RNA-based platform to screen for colorectal cancer and
advanced adenomas for average-risk individuals over the age of 45.
In partnership with leading universities and biopharmaceutical
companies, Geneoscopy is also developing diagnostic tests for
treatment selection and therapy monitoring in other GI disease
areas. For more information, visit www.geneoscopy.com and follow
the company on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240524737724/en/
Media: Andrea Sampson Sampson Public Relations Group
asampson@sampsonprgroup.com
Investor Relations: Carrie Mendivil / Ji-Yon Yi Gilmartin
Group investors@geneoscopy.com